SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

计划入组 48 人 · 首次发布于 2025 年 10 月 30 日

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

计划入组 13 人 · 首次发布于 2020 年 11 月 16 日

Intranasal SB-705498 in Healthy Volunteers

计划入组 44 人 · 首次发布于 2009 年 5 月 25 日

SB-756050

SB-8091

SB-271046

SB PHARMA LIMITED

Hong Kong, China

SB FUNCTIONAL HEALTH GROUP PTY LTD

Australia

ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA SOCIETA' BENEFIT

Italy

CIT Therapeutics Secures $2.5M Partnership with IFLI to Advance Novel SUMOylation-Targeted Cancer Therapy

Spine BioPharma Completes Enrollment in Phase 3 Trial of SB-01 for Chronic Low Back Pain

CARsgen Partners with Zhuhai SB Xinchuang to Advance Allogeneic CAR-T Development in China